Reverion raised 8.5 million euro invest

26.04.2023

We are very happy to welcome a new game-changer in our portfolio: Reverion, the climate tech start-up for renewable energies, raised EUR 8.5 million! UVC Partners, Green Generation Fund, Extantia Capital, Doral Energy-Tech Ventures, and biomethane trader Landwärme GmbH participated in the round.

The investors' fresh capital will be used to expand the production of 100 kW and 500 kW biogas power plants. Why will Reverion change the energy industry with its technology?

⚡ Existing biogas operators can increase their revenue by up to 400 percent using the same amount of biomass

⚡ Reverion’s modular power plants can double the efficiency of electricity generation from 40 to 80 percent compared to conventional technology of biogas suppliers

⚡ Since the small power plants can also run "backward" (reversible), a renewable natural gas substitute or green hydrogen can be produced and stored from a temporary surplus in the wind and solar power to make renewable energy supply more stable

Reverion’s modern power plants can be operated CO2-negatively when biogas is used

Johannes von Borries, Managing Director at UVC Partners: "We looked at various start-ups in this area. The founding team of Reverion convinced us because they have developed an outstanding technology over the last years and successfully tested it in a pilot plant. With our large network together with UnternehmerTUM, we can bring partners, suppliers, and expertise to the table to further scale the technology."

A cordially welcome to Reverion and the whole team! Great to have you on board!

? Read more in our press release: https://lnkd.in/eXpwSR3g

Diesen Artikel teilen

Gallerie

Ähnliche Themen

Simplyfined erhält Millionen-Förderung vom Bund

06.11.2024

1,7 Millionen Euro über zwei Jahre erhält das Gründerteam der TU Dortmund. Simplyfined arbeitet daran, Oleochemikalie...

Weiterlesen

Akribion Therapeutics GmbH sichert sich erste Seed-Finanzierungsrunde

05.11.2024

Akribion Therapeutics hat seine erste Seed-Finanzierungsrunde erfolgreich abgeschlossen und wird am 1. Dezember 2024 ...

Weiterlesen

BRAIN Biotech: Abspaltung von Akribion

01.11.2024

Akribion Therapeutics schließt einen exklusiven Lizenzvertrag mit der BRAIN Biotech AG für ihre CRISPR/Cas-Technologi...

Weiterlesen